AstraZeneca Annual Report and Financial Statements 62 Form 20-F Information 2003 Group Profit and Loss Account for the year ended 31 December Before exceptional Exceptional 2003 items items Total Notes $m $m $m Group turnover 18,849 18,849 Operating costs 1 14,938 14,938 Other operating income 1 200 200 Group operating profit 1 4,111 4,111 Share of operating profits of joint ventures and associates 2 Profits on sale of fixed assets 3 Dividend income 2 2 Profit on ordinary activities before interest 4,113 4,113 Net interest 489 89 Profit on ordinary activities before taxation 4,202 4,202 Taxation 5 1,143 1,143 Profit on ordinary activities after taxation 3,059 3,059 Attributable to minorities 23 23 Net profit for the financial year 3,036 3,036 Dividends to shareholders 6 1,350 Profit retained for the financial year 1,686 Earnings per $0.25 Ordinary Share before exceptional items 7 $1.78 $1.78 Earnings per $0.25 Ordinary Share basic 7 $1.78 $1.78 Earnings per $0.25 Ordinary Share diluted 7 $1.78 $1.78 Weighted average number of Ordinary Shares in issue millions 7 1,709 All activities were in respect of continuing operations.
There were no material differences between reported profits and losses and historical cost profits and losses on ordinary activities before taxation.
Group Statement of Total Recognised Gains and Losses for the year ended 31 December 2003 Notes $m Net profit for the financial year 3,036 Foreign exchange adjustments on consolidation 20 1,361 Tax on foreign exchange adjustments on consolidation 20 66 Translation differences on foreign currency borrowings 20 Tax on translation differences on foreign currency borrowings 20 Total recognised gains and losses relating to the financial year 4,463 $m means millions of US dollars
